He has turned this into a daily trading stock and it will stay that way until he has something besides the usual conferences with old data. How many times can he say look at me I'm great.
I agree and yet longs have recently stated they wished for a partner for this one.
Gary, I received an answer last week. It was mostly generic in nature, very non committal. Also said they were not able to comment further on some of my more detailed questions at this time, although there isn't any reason I can see. What ever the reasons, I think the same reason is holding up the partnership negotiations and news in general. I do not think it is disregard for shareholders, I think it is something more.
We expected more because Dr. Kim categorized them as "low hanging fruit". To go along with the dwarfing comment and that set the stage for raised expectations. Reap what you sow.
Or they are in a quiet period and can't comment on anything. Driving the pps and market cap down makes this cheap. I can see Roche walking on 5150 knowing their exit would cause the pps to drop. Can you see them protecting their adjuvant? I can see Merk and Roche and one or two others talking buyout at this point. Too quiet for me.
I have quality in Boeing and Corning, and now INCY which I sold recently. I don't know what is going on behind the scenes for sure. I suspect there are negotiations going on and that we could be in a silent period. I can't justify Roche walking unless they are protecting their own adjuvants and don't want a competitor knowing what they are doing. Just a guess on my part due to the golden parachute to the CMO on November 7th. Too much happened in a short time without good explanations. That happens when changes in ownership or management is a possibility. Things like that make me think, so it is all just my opinion. I think the same thing is going on here in Wilmington with INCY, again just my opinion. I do try to look down the road and be ahead of the trade which is really difficult, and seem more so every day. What I post is usually to illicit other replies from some of the thinkers and more knowledgeable here and hope it is taken that way and not and indictment of the company. I also think management should be accountable to the shareholders, that ain't gonna happen.
Nothing you said I can disagree with. Money in the bank is good, just not enough. Partnerships are necessity but longs like Permit say we don't need them, more money for us. Couldn't be more wrong, no thought process there. All these trials cost big and we need the financial help and the validation it brings. When it comes to marketing, we need them even more. These retail $2 investors can't see what all this entails and it shows in their posts. Enjoy some of the commentary here, but not much of it. "More starting soon" and a portfolio that could choke a horse. The more money we have available the faster to trial and market. That's the bottom line.
Well, that's my feeling this morning anyway. So much going on for one man to handle. Burden is huge there with trials on going and new ones to get started. Gotta stay focused.
Is huge in this business and this year's results are going to test this company's credibility for sure. Lots of raised expectations to fulfill and not much time left to do it. Advancing the science was almost right on target.
Financially, it was another story and one that will haunt us for a long time it appears. Raising cash at this point is going to be much more costly than it could of been and that is weighing heavily on the pps. Without partnerships to ease the process, we will drift lower and the RS will hang over us much longer than it should of. Timing for that issue was critical and so far it seems to have been done too early, time will eventually tell the whole story. Wishing Dr. Kim and the BOD better success in 2015, but would rather see some change at the top. Would like to see Dr. Kim in the lab, too many balls in the air for a fast growing small company on the verge of new and exciting vaccines for cancer and diseases. Surely the responsibilities are enormous for one man.
If they found it so attractive in July, why aren't we seeing more buying here? From $17 to $8 it is having an effect. Insiders standing pat because they are so far under water. Next round of financing at these levels is awful for shareholders, talk about costly.